Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypertension in the elderly.

P Larochelle1

  • 1Institut de Recherches Cliniques de Montréal, Hôtel-Dieu de Montréal, Quebec, Canada.

Cardiovascular Drugs and Therapy
|August 1, 1990
PubMed
Summary
This summary is machine-generated.

Elderly hypertension management is crucial for reducing cardiovascular mortality. While systolic pressure is key in older adults, more research is needed on long-term benefits of newer agents like calcium channel blockers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement of Reactor Antineutrino Oscillation at SNO.

Physical review letters·2025
Same author

Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents.

Current oncology (Toronto, Ont.)·2012
Same author

Antihydrogen production within a Penning-Ioffe trap.

Physical review letters·2008
Same author

Antiproton confinement in a Penning-Ioffe trap for antihydrogen.

Physical review letters·2007
Same author

Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group.

Journal of hypertension·2001
Same author

Adverse events associated with prescription drug cost-sharing among poor and elderly persons.

JAMA·2001
Same journal

GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease.

Cardiovascular drugs and therapy·2026
Same journal

Methodological Considerations in Evaluating Plaque Stabilization in Patients with High Lipoprotein(a).

Cardiovascular drugs and therapy·2026
Same journal

Association of In-Hospital Dapagliflozin Initiation with Favorable left Ventricular Remodeling in Patients with Acute Myocardial Infarction and Heart Failure: A Retrospective Cohort Study.

Cardiovascular drugs and therapy·2026
Same journal

Impact of Nitric Oxide Metabolites On Early Perioperative Biochemical Changes and Postoperative Complications in High-BMI Patients Undergoing On-Pump CABG: an Exploratory Observational Cohort Study.

Cardiovascular drugs and therapy·2026
Same journal

Comparative Cardiovascular, Lipid, and Safety Effects of Lipid-Modifying Therapies in Diabetes: An Agent-, Class-, and Dose-Level Network Meta-Analysis.

Cardiovascular drugs and therapy·2026
Same journal

Cardiovascular Genetic Epidemiology in the Genome-Wide Era: From Association Discovery to Mechanistic Dissection and Clinical Translation.

Cardiovascular drugs and therapy·2026
See all related articles

Area of Science:

  • Gerontology
  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) significantly impacts the elderly, with hypertension as a primary risk factor.
  • Systolic blood pressure is increasingly recognized as a critical risk factor for CVD complications in older adults.
  • Existing drug trials suggest hypotensive treatments can reduce cardiovascular and cerebrovascular mortality in the elderly.

Purpose of the Study:

  • To review the current understanding of hypertension management in the elderly.
  • To evaluate the role of different antihypertensive drug classes in this population.
  • To identify gaps in knowledge regarding long-term treatment efficacy, particularly for newer agents.

Main Methods:

  • Review of existing intervention drug trials in elderly hypertensive patients.

Related Experiment Videos

  • Analysis of studies on the efficacy and safety of antihypertensive medications, including older and newer agents.
  • Examination of pharmacokinetic data in elderly populations.

    • Main Results:

    • Diuretic combinations and beta-blockers have been studied, with some evidence of mortality reduction.
    • Calcium antagonists show potential efficacy in the elderly, but further validation is required.
    • Limited pharmacokinetic data suggests reduced clearance in the elderly; Nifedipine Retard shows promise but lacks long-term outcome data.

    Conclusions:

    • Hypotensive drug treatment can decrease cardiovascular mortality in the elderly, primarily through reduced cerebrovascular events.
    • The long-term benefits of newer agents like ACE inhibitors and calcium channel blockers in elderly hypertension require further investigation.
    • More clinical trials are needed to establish the definitive role and long-term efficacy of specific agents, such as nifedipine, in managing hypertension in older adults.